Coherus Biosciences Inc (NASDAQ: CHRS)’s stock price has soared by 0.23 in relation to previous closing price of 2.15. Nevertheless, the company has seen a loss of -12.04% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-20 that CHRS has sold Cimerli, a Lucentis biosimilar, to SDZNY. CHRS anti-IL-27 antibody, casdozokitug, shows promising results as part of a triple therapy in hepatocellular carcinoma, with an overall response rate of 38%. Numbers on market share point to a strong Q1’24 for Udenyca, which could increase the market’s confidence that CHRS can offset lost revenues from the Cimerli sale.
Is It Worth Investing in Coherus Biosciences Inc (NASDAQ: CHRS) Right Now?
The 36-month beta value for CHRS is at 0.53. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CHRS is 106.17M, and currently, shorts hold a 22.09% of that float. The average trading volume for CHRS on April 17, 2024 was 3.39M shares.
CHRS’s Market Performance
The stock of Coherus Biosciences Inc (CHRS) has seen a -12.04% decrease in the past week, with a -2.93% drop in the past month, and a -12.40% fall in the past quarter. The volatility ratio for the week is 6.71%, and the volatility levels for the past 30 days are at 6.93% for CHRS. The simple moving average for the past 20 days is -9.22% for CHRS’s stock, with a -32.91% simple moving average for the past 200 days.
Analysts’ Opinion of CHRS
Many brokerage firms have already submitted their reports for CHRS stocks, with Robert W. Baird repeating the rating for CHRS by listing it as a “Outperform.” The predicted price for CHRS in the upcoming period, according to Robert W. Baird is $11 based on the research report published on November 17, 2023 of the previous year 2023.
Citigroup gave a rating of “Buy” to CHRS, setting the target price at $12 in the report published on July 24th of the previous year.
CHRS Trading at -10.07% from the 50-Day Moving Average
After a stumble in the market that brought CHRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.09% of loss for the given period.
Volatility was left at 6.93%, however, over the last 30 days, the volatility rate increased by 6.71%, as shares sank -11.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.93% upper at present.
During the last 5 trading sessions, CHRS fell by -11.84%, which changed the moving average for the period of 200-days by -49.41% in comparison to the 20-day moving average, which settled at $2.36. In addition, Coherus Biosciences Inc saw -35.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CHRS starting from Lanfear Dennis M, who sale 223,100 shares at the price of $2.02 back on Nov 22 ’23. After this action, Lanfear Dennis M now owns 731,693 shares of Coherus Biosciences Inc, valued at $449,770 using the latest closing price.
Stock Fundamentals for CHRS
Current profitability levels for the company are sitting at:
- -0.79 for the present operating margin
- 0.38 for the gross margin
The net margin for Coherus Biosciences Inc stands at -0.92. The total capital return value is set at -0.68.
Based on Coherus Biosciences Inc (CHRS), the company’s capital structure generated 1.69 points at debt to capital in total, while cash flow to debt ratio is standing at -0.37. The debt to equity ratio resting at -2.46. The interest coverage ratio of the stock is -10.13.
Currently, EBITDA for the company is -189.41 million with net debt to EBITDA at -1.91. When we switch over and look at the enterprise to sales, we see a ratio of 2.4. The receivables turnover for the company is 0.99for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.43.
Conclusion
In conclusion, Coherus Biosciences Inc (CHRS) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
